Journal article

Relaxin family peptide receptors - from orphans to therapeutic targets

Emma T van der Westhuizen, Michelle L Halls, Chrishan S Samuel, Ross AD Bathgate, Elaine N Unemori, Steven W Sutton, Roger J Summers

DRUG DISCOVERY TODAY | ELSEVIER SCI LTD | Published : 2008

Abstract

The relaxin family peptides have distinct expression profiles and physiological functions. Several of them are the cognate ligands for 4 G-protein-coupled relaxin family peptide receptors (RXFPs; formerly LGR7, LGR8, GPCR135, GPCR142). The relaxin/RXFP1 system has roles in reproductive physiology but is also involved in fibrosis, wound healing and responses to infarction. Relaxin has a potential use in congestive heart failure where fibrosis plays an important role in organ failure. The INSL3/RXFP2 system has biological roles in reproductive biology that may have limited therapeutic potential. However, the recently characterized relaxin-3/RXFP3 system is important in stress/anxiety and body ..

View full abstract

Grants

Funding Acknowledgements

This work was supported by the National Health and Medical Research Council (NHMRC) of Australia and by the Australian Research Council. Emma T. van der Westhuizen is a NHMRC Dora Lush (Biomedical) Post Graduate Scholar and Michelle L. Halls is an Australian Postgraduate Scholar and recipient of a Monash University Faculty of Medicine, Nursing and Health Sciences Excellence Award. Ross A.D. Bathgate is a NHMRC Senior Research Fellow and Chrishan S. Samuel is a National Heart Foundation of Australia (NHFA)/NHMRC R.D. Wright Fellow. Steven W. Sutton is a Senior Scientist at Johnson & Johnson Pharmaceutical Research & Development, LLC, whose work was solely supported by that company.